Keywords
Elderly patients
Immune function
Submitted : 2025-05-01
Accepted : 2025-05-16
Published : 2025-05-31
Abstract
Objective: To investigate the effects of nebulized α-interferon on immune function in elderly patients with respiratory tract infection. Methods: A total of 120 elderly patients with respiratory tract infection admitted to our hospital from June 2023 to June 2024 were selected and randomly divided into an observation group (n=60) and a control group (n=60) using the envelope method. The control group received conventional treatment, while the observation group received additional nebulized α-interferon therapy based on conventional treatment. After the same treatment period, changes in immune function indicators (immunoglobulins IgG, IgA, IgM) were compared between the two groups. Patients were also followed up for 3 months to observe the frequency of respiratory tract infection recurrences. Results: After treatment, IgA and IgM levels decreased significantly, while IgG levels increased significantly in both groups. The improvement in each indicator was more pronounced in the observation group than in the control group (P < 0.05). By the end of the follow-up period, all 120 patients had successfully completed the follow-up, and no patients were lost to follow-up. The frequency of respiratory tract infection recurrences was lower in the observation group than in the control group (P < 0.05). Conclusion: Nebulized α-interferon can improve immune function and reduce the frequency of recurrences in elderly patients with respiratory tract infection.
References
Yan C, Shan H, Pei X, et al., 2022, Analysis of the Efficacy and Safety of Shufeng Jiedu Capsule Combined With a-Interferon and Abidol in the Treatment of Common Type Coronavirus Disease 2019. Journal of Guangzhou University of Chinese Medicine, 39(3): 475–480.
Liu Y, 2021, Effect of Abidol Combined With a-Interferon Atomization Inhalation in the Treatment of COVID-19 and Its Influence on Nucleic Acid and IgM Antibody Negative Conversion Rate. The Journal of Medical Theory and Practice, 34(9): 1499–1501.
Tian C, Xiang M, 2020, Feasibility Analysis of Remdesivir Combined With a-Interferon in the Treatment of Coronavirus Disease 2019. Herald of Medicine, 39(4): 477–482.
Yu S, Zhang Y, Wang N, et al., 2024, Study on the Etiological Characteristics of Lower Respiratory Tract Infection in Elderly Patients With AECOPD and Its Relationship With Inflammatory Immune Balance. Progress in Modern Biomedicine, 24(14): 2650–2655+2671.
Klouda T, Hao Y, Kim H, et al., 2022, Interferon-Alpha or -Beta Facilitates SARS-CoV-2 Pulmonary Vascular Infection by Inducing ACE2. Angiogenesis, 25(2): 225–240.
Zhao C, Li R, Huang H, 2021, Clinical Study on the Efficacy and Safety of Moxifloxacin Combined With Pidotimod in the Treatment of Respiratory Infections in the Elderly. Chinese and Foreign Medical Research, 40(14): 83–86.
Hadjadj J, Yatim N, Barnabei L, et al., 2020, Impaired Type I Interferon Activity and Inflammatory Responses in Severe COVID-19 Patients. Science, 369(6504): 718–724.
Kong Y, Wang X, Li X, et al., 2019, Evaluation of the Efficacy and Cellular Immune Indicators of Moxifloxacin Combined With Pidotimod in the Treatment of Respiratory Infections in Elderly Patients. Chinese Journal of Clinical Healthcare, 22(6): 814–817.
Yang L, Wang J, Hui P, et al., 2021, Potential Role of IFN-a in COVID-19 Patients and Its Underlying Treatment Options. Applied Microbiology and Biotechnology, 105(10): 4005–4015.
Yin H, Liu H, 2019, Observation of Tanreqing Application and Evaluation of Cellular Immune Indicators in Elderly Patients With Respiratory Tract Infection. Journal of Clinical Medical Literature (Electronic Edition), 6(18): 161.